Trial
NCT05516758
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
Peresolimab
Why stopped
Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-04